Pharmaceutical Market Access in Developed Markets

Güvenç Koçkaya, Albert Wertheimer

Pubblication date January 2018
Language
Format 17 x 24 cm
Number pages 324
ISBN 978-88-97419-73-0
ISBN e-book 978-88-97419-74-7 Buy ebook

Sorry, this entry is only available in Italian. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.

Market access is the process by which a pharmaceutical company gets its product available on the market after having obtained a marketing authorization from a regulatory agency and by which the product becomes available for all patients for whom it is indicated as per its marketing authorization.
It covers a group of activities intended to provide access to the appropriate medicine for the appropriate group of patients at the appropriate price (in most countries). Market Access may also be seen as activities that support the management of potential barriers, such as non-optimal price and reimbursement levels, the restriction of the scope of prescribing for the drug or complicated prescription writing or funding procedures.
Since there are cultural differences among countries, any Market Access strategy needs to be culturally sensitive.
Pharmaceutical Market Access in emerging markets has been extensively discussed in our previous book, published in 2016. The present book focuses on developed markets with the goal of helping students, academics, industry personnel, government workers, and decision makers understand the environment in developed markets.

Target

Academics, decision makers, government workers, personnel of pharmaceutical industry, students, teachers.

30,00

Güvenç Koçkaya, Albert Wertheimer

Sorry, this entry is only available in Italian. For the sake of viewer convenience, the content is shown below in the alternative language. You may click the link to switch the active language.

Market access is the process by which a pharmaceutical company gets its product available on the market after having obtained a marketing authorization from a regulatory agency and by which the product becomes available for all patients for whom it is indicated as per its marketing authorization.
It covers a group of activities intended to provide access to the appropriate medicine for the appropriate group of patients at the appropriate price (in most countries). Market Access may also be seen as activities that support the management of potential barriers, such as non-optimal price and reimbursement levels, the restriction of the scope of prescribing for the drug or complicated prescription writing or funding procedures.
Since there are cultural differences among countries, any Market Access strategy needs to be culturally sensitive.
Pharmaceutical Market Access in emerging markets has been extensively discussed in our previous book, published in 2016. The present book focuses on developed markets with the goal of helping students, academics, industry personnel, government workers, and decision makers understand the environment in developed markets.

Güvenç Koçkaya, Albert Wertheimer

Pubblication date January 2018
Language
Format 17 x 24 cm
Number pages 324
ISBN 978-88-97419-73-0
ISBN e-book 978-88-97419-74-7 Buy ebook

Authors

Güvenç Koçkaya
CarthaGenetics, Pully, Switzerland

Albert Wertheimer
College of Pharmacy, Nova Southeastern University, Ft. Lauderdale, FL, USA

Summary

  • Preface
  • Introduction to the Market Access
  • Market Access in Germany
  • Market Access in the UK
  • Market Access in France
  • Market Access in Italy
  • Market Access in Spain
  • Market Access in Portugal
  • Pharmaceutical Market Access in Denmark, Sweden and the Netherlands: an Overview
    Market Access in Japan
  • Market Access in Australia
  • Market Access in New Zealand
  • Pharmaceutical Market in the U.S: a Brief Treatis
  • Pharmaceutical Market in Canada: a Brief Treatise
  • Pharmaceutical Market Access Hurdles in Developed Countries
  • Role of Health Technology Assessment in Pharmaceutical Market Access in Developed Countries
  • Impact of the International Reference Pricing on Pharmaceutical Market Access
  • General Overview of Value-Based Pricing
  • The Role of Patients in Market Access
  • The Challenges and Future of Advanced Therapies

You may also like…